Hepatitis-C-Virus - Viruskinetik und Resistenzmechanismen

In-vitro

[1]  A. Perelson,et al.  Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV , 2004, Journal of acquired immune deficiency syndromes.

[2]  A. Perelson,et al.  Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. , 2003, The Journal of infectious diseases.

[3]  A. Neumann,et al.  Slow viral dynamics of hepatitis C virus genotype 4 , 2003, Journal of viral hepatitis.

[4]  N. Enomoto,et al.  Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  A. Perelson,et al.  Dynamics of alanine aminotransferase during hepatitis C virus treatment , 2003, Hepatology.

[6]  A. Perelson,et al.  Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin , 2003, Hepatology.

[7]  E. Herrmann,et al.  Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon , 2003, Hepatology.

[8]  Stanley M. Lemon,et al.  Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease , 2003, Science.

[9]  L. Terracciano,et al.  Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. , 2003, Gastroenterology.

[10]  Jin-Xiong She,et al.  Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line , 2003, Hepatology.

[11]  U. Mihm,et al.  Detection of mutations necessary for HCV replication in the in vitro replicon system in patients with chronic hepatitis C , 2003 .

[12]  Y. Karino,et al.  Hepatitis C virus genotypes and hepatic fibrosis regulate 24‐h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C , 2003, Journal of gastroenterology and hepatology.

[13]  B. Kronenberger,et al.  Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. , 2003, The Journal of infectious diseases.

[14]  C. Rice,et al.  New therapies on the horizon for hepatitis C: are we close? , 2003, Clinics in liver disease.

[15]  C. Datz,et al.  Early viral kinetics on treatment with pegylated interferon‐α‐2a in chronic hepatitis C virus genotype 1 infection * , 2003, Journal of viral hepatitis.

[16]  A. Neumann,et al.  First phase hepatitis c viral kinetics in previous nonresponders patients , 2003, Journal of viral hepatitis.

[17]  E. Herrmann,et al.  Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses , 2002, Journal of Virology.

[18]  Rachel S. Levy-Drummer,et al.  First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline , 2002, Journal of viral hepatitis.

[19]  Rachel S. Levy-Drummer,et al.  Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C , 2002, Journal of viral hepatitis.

[20]  S. Chou,et al.  Analysis of Sequence Configurations of the ISDR, PKR-Binding Domain, and V3 Region as Predictors of Response to Induction Interferon-α and Ribavirin Therapy in Chronic Hepatitis C Infection , 2002, Digestive Diseases and Sciences.

[21]  K. Murase,et al.  Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon , 2002, American Journal of Gastroenterology.

[22]  M. Buti,et al.  Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa‐2b plus ribavirin , 2002, Hepatology.

[23]  E. Herrmann,et al.  Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. , 2001, Virology.

[24]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[25]  R. Xavier,et al.  Hepatitis C virus replication is directly inhibited by IFN-α in a full-length binary expression system , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  N. Sinelli,et al.  Clearance kinetics of hepatitis C virus under different antiviral therapies , 2001, Journal of medical virology.

[27]  G. Barber,et al.  Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response , 2001, Journal of Virology.

[28]  A. Neumann,et al.  Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. , 2001, Gastroenterology.

[29]  A. Hinnebusch,et al.  Hepatitis C Virus Envelope Protein E2 Does Not Inhibit PKR by Simple Competition with Autophosphorylation Sites in the RNA-Binding Domain , 2001, Journal of Virology.

[30]  Philip Beineke,et al.  Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response , 2001, Journal of medical virology.

[31]  A. Alberti,et al.  Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. , 2000, Gastroenterology.

[32]  T. Berg,et al.  Mutations in the E2‐PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment , 2000, Hepatology.

[33]  B. Wiedenmann,et al.  Einfluss von Ribavirin auf die Dynamik der Hepatitis-C-Virämie bei Interferon-α-behandelten Patienten mit Response oder Nonresponse , 2000 .

[34]  J. Albrecht,et al.  The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. , 2000, Gastroenterology.

[35]  S. Ray,et al.  Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy , 2000, Journal of Virology.

[36]  S. Polyak,et al.  The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. , 2000, The Journal of infectious diseases.

[37]  A S Perelson,et al.  Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. , 2000, The Journal of infectious diseases.

[38]  G. Duverlie,et al.  Expression of Hepatitis C Virus Proteins Interferes with the Antiviral Action of Interferon Independently of PKR-Mediated Control of Protein Synthesis , 2000, Journal of Virology.

[39]  B. Kronenberger,et al.  Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. , 2000, Hepatology.

[40]  P. Mills,et al.  The NS5a gene of hepatitis C virus in patients treated with interferon‐α , 2000, Journal of medical virology.

[41]  T. Berg,et al.  Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. , 2000, The Journal of infectious diseases.

[42]  H. Thomas,et al.  Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. , 1999, Gastroenterology.

[43]  N. Enomoto,et al.  Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection , 1999, Hepatology.

[44]  H. Blum,et al.  Expression of Hepatitis C Virus Proteins Inhibits Signal Transduction through the Jak-STAT Pathway , 1999, Journal of Virology.

[45]  William M. Lee,et al.  Racial differences in responses to therapy with interferon in chronic hepatitis C , 1999, Hepatology.

[46]  R. Chung,et al.  Mutations in the NS5A region do not predict interferon‐responsiveness in American patients infected with genotype 1b hepatitis C virus , 1999, Journal of medical virology.

[47]  D. R. Taylor,et al.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.

[48]  W K Roth,et al.  Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. , 1999, Journal of hepatology.

[49]  S. Polyak,et al.  Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon‐sensitive virus replication , 1999, Hepatology.

[50]  N. Horiike,et al.  Relationship between the effect of interferon therapy and the change of hepatitis C virus non‐structural 5B gene , 1999, Journal of gastroenterology and hepatology.

[51]  H. Hotta,et al.  The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. , 1999, The Journal of general virology.

[52]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[53]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[54]  Jinhong Chang,et al.  Relationship between interferon therapy and variability in nonstructural gene 5b of hepatitis C virus , 1998, Journal of Gastroenterology.

[55]  J. Odeberg,et al.  Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment , 1998, Journal of medical virology.

[56]  Michael G. Katze,et al.  Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation , 1998, Molecular and Cellular Biology.

[57]  C. Rice,et al.  Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins , 1998, Hepatology.

[58]  J. Schmidt,et al.  Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover , 1998, Hepatology.

[59]  O. Jaillon,et al.  Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. , 1998, The Journal of general virology.

[60]  J. Dopazo,et al.  The prognostic relevance of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. , 1998, The Journal of infectious diseases.

[61]  A. Neumann,et al.  Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations , 1998, Journal of Virology.

[62]  T. Fujisawa,et al.  Mutations in the nonstructural protein 5A gene and response to interferon therapy in young patients with chronic hepatitis C virus 1b infection , 1997, Journal of medical virology.

[63]  S. Polyak,et al.  Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b , 1997, Journal of medical virology.

[64]  C. Bréchot,et al.  Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. , 1997, Gastroenterology.

[65]  A. Neumann,et al.  Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.

[66]  L. Stuyver,et al.  Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. , 1997, Journal of hepatology.

[67]  M. Katze,et al.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. , 1997, Virology.

[68]  N. Enomoto,et al.  Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon‐β therapy , 1997, Hepatology.

[69]  S. Zeuzem,et al.  Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa , 1997, Hepatology.

[70]  K. Chayama,et al.  Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection , 1997, Hepatology.

[71]  J. Schmidt,et al.  Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo , 1996, Hepatology.

[72]  N Enomoto,et al.  Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. , 1996, The New England journal of medicine.

[73]  N. Enomoto,et al.  Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. , 1995, The Journal of clinical investigation.

[74]  P. Simmonds.  Variability of hepatitis C virus , 1995, Hepatology.

[75]  N. La Monica,et al.  Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. , 2004, Gastroenterology.

[76]  小林 真.  Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon , 2004 .

[77]  P. Kuzmič,et al.  Effect of Ribavirin and Amantadine on Early Hepatitis C Virus RNA Rebound and Clearance in Serum During Daily High-Dose Interferon , 2004, Digestive Diseases and Sciences.

[78]  J. Layden-Almer,et al.  Viral Kinetics in Hepatitis C Virus: Special Patient Populations , 2003, Seminars in liver disease.

[79]  E. Herrmann,et al.  Pharmacokinetics of Peginterferons , 2003, Seminars in liver disease.

[80]  Andrew H Talal,et al.  Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. , 2003, Seminars in liver disease.

[81]  P. Bonneau,et al.  An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003 .

[82]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[83]  齋藤 剛.  Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b , 2002 .

[84]  K. Abid,et al.  Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance. , 2000, Science.

[85]  山本 力.  Nucleotide Sequence Variations in the Internal Ribosome Entry Site of Hepatitis C Virus-1b : No Association With Efficacy of Interferon Therapy or Serum HCV-RNA Levels , 1999 .

[86]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[87]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[88]  T. Mondala,et al.  Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. , 1996, Journal of viral hepatitis.